Literature DB >> 15019274

Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells.

Peter Riis Hansen1, Klaus Rieneck, Klaus Bendtzen.   

Abstract

BACKGROUND: The mineralocorticoid receptor antagonist spironolactone (SPIR) reduces the mortality and morbidity in patients with congestive heart failure (CHF). Overexpression of proinflammatory cytokines contribute to the development and progression of CHF.
MATERIAL AND METHODS: We examined the effect of SPIR on in vitro cytokine production by human peripheral blood mononuclear cells (PBMC). PBMC were cultured with 10-1000 microM SPIR and stimulated with lipopolysaccharide or phytohaemagglutinin-P. Tumour necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, IL-1beta, and interferon (IFN)-gamma were measured in culture supernatants by enzyme-linked immunosorbent assay and mRNA expression of the cytokines was determined by real-time reverse transcriptase polymerase chain reaction (PCR).
RESULTS: SPIR inhibited the stimulated production of TNF-alpha, IL-6, and IFN-gamma, whereas the release of IL-1beta was not significantly affected. The SPIR-induced cytokine inhibition occurred at the transcriptional level and was independent of antimineralocorticoid and antiandrogen activities.
CONCLUSION: The findings suggest that inhibited production of proinflammatory cytokines may be an extrarenal mechanism that contributes to the beneficial effect of SPIR in patients with CHF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15019274     DOI: 10.1016/j.imlet.2003.11.008

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  16 in total

1.  Eplerenone inhibits tumour necrosis factor alpha shedding process by tumour necrosis factor alpha converting enzyme in monocytes from patients with congestive heart failure.

Authors:  M Satoh; Y Ishikawa; Y Minami; T Akatsu; M Nakamura
Journal:  Heart       Date:  2006-07       Impact factor: 5.994

Review 2.  Systemic inflammation in heart failure--the whys and wherefores.

Authors:  Arne Yndestad; Jan Kristian Damås; Erik Oie; Thor Ueland; Lars Gullestad; Pål Aukrust
Journal:  Heart Fail Rev       Date:  2006-03       Impact factor: 4.214

3.  Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling.

Authors:  Jason M Elinoff; Li-Yuan Chen; Edward J Dougherty; Keytam S Awad; Shuibang Wang; Angelique Biancotto; Afsheen H Siddiqui; Nargues A Weir; Rongman Cai; Junfeng Sun; Ioana R Preston; Michael A Solomon; Robert L Danner
Journal:  Cardiovasc Res       Date:  2018-01-01       Impact factor: 10.787

4.  The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis.

Authors:  Emanuel Zitt; Kathrin Eller; Julia M Huber; Alexander H Kirsch; Andrea Tagwerker; Gert Mayer; Alexander R Rosenkranz
Journal:  Int J Clin Exp Pathol       Date:  2011-08-03

5.  Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha.

Authors:  C A Carvajal; A A Herrada; C R Castillo; F J Contreras; C B Stehr; L M Mosso; A M Kalergis; C E Fardella
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

6.  Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis induction.

Authors:  Søren Ulrik Salling Sønder; Marianne Mikkelsen; Klaus Rieneck; Chris Juul Hedegaard; Klaus Bendtzen
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

7.  Ethinylestradiol30μg-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome?

Authors:  Ioana Rada Ilie; Ioan Marian; Teodora Mocan; Razvan Ilie; Lucian Mocan; Ileana Duncea; Carmen Emanuela Pepene
Journal:  BMC Endocr Disord       Date:  2012-06-19       Impact factor: 2.763

8.  A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial.

Authors:  Jason M Elinoff; J Eduardo Rame; Paul R Forfia; Mary K Hall; Junfeng Sun; Ahmed M Gharib; Khaled Abd-Elmoniem; Grace Graninger; Bonnie Harper; Robert L Danner; Michael A Solomon
Journal:  Trials       Date:  2013-04-02       Impact factor: 2.279

Review 9.  Pharmacological and non-pharmacological interventions to influence adipose tissue function.

Authors:  Jan Westerink; Frank L J Visseren
Journal:  Cardiovasc Diabetol       Date:  2011-01-28       Impact factor: 9.951

10.  Intrathecal injection of spironolactone attenuates radicular pain by inhibition of spinal microglia activation in a rat model.

Authors:  Yu-e Sun; Liangyu Peng; Xiaofeng Sun; Jinhua Bo; Dong Yang; Yaguo Zheng; Chenglong Liu; Beibei Zhu; Zhengliang Ma; Xiaoping Gu
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.